乙肝Ⅲ号内外合用对慢性乙型肝炎患者肝纤维化指标和血液动力学的影响

Influence of internal combined with external application of Yigan Sanhao on liver fibrosis and hemodynamics in chronic hepatitis B patients

目的:观察乙肝Ⅲ号内外合用对慢性乙型肝炎患者肝纤维化指标和血液动力学的影响。方法:选择慢性乙型肝炎患者120例,分为外用组(29例)、内服组(30例)、合用组(32例)和对照组(29例),其中对照组用保肝降酶基础治疗,其他3组在基础治疗上分别加用乙肝Ⅲ号外敷、内服、内外合用3种不同方法。1个月为1个疗程,连续治疗3个疗程,观察患者肝功能、肝纤维化3项指标以及血液动力学变化。结果:在改善肝功能方面:治疗1个月时各组间比较差异无显著性意义,治疗3个月时,外用组、内服组、对照组与合用组比较,差异有显著性意义(P<0.01或P<0.05),以合用组疗效为优。在改善肝纤维化指标方面:外用组、内服组、合用组3组患者治疗前与本组治疗3个月后比较,差异均有显著性意义(P<0.01),合用组与其他各组比较,差异有显著性意义(P<0.01)。血液动力学方面,外用组、内服组、合用组患者治疗前与治疗3个月时比较脾静脉D、Q值皆有下降,差异具有显著性意义(P<0.01或P<0.05),合用组患者血流量下降明显;3组患者D、Q值与对照组比较差异具有显著性意义(P<0.01);结论:乙肝Ⅲ号内外合用治疗慢性乙型肝炎临床疗效确切,且较单一方法疗效明显,疗程以3个月为优。可有效改善肝功能、降低肝纤维化程度、有效改善血液动力学变化。

Objective：To observe the influence of internal combined with external application of Yigan Sanhao（YGSH） in treatment of hepatitis B patients.Methods： A total of 120 chronic Hepatitis B patients were divided into external application of YGSH group（n=29）,internal application of YGSH group（n=30）,combined group（n=32） and control group（n=29）.Patients in control group were treated with the basis of general treatment of protecting the liver and falling the enzyme,other 3 groups separately add three different methods with YGSH externally apply,take orally,combined treatment in the basis of general treatment.One month was one period of treatment,and treated for 3 months.Observed the changes of liver function、3 indexes of liver fibrosis and hemodynamic changes.Results：In the aspects of improving liver function,the differences of 4 groups were not to be obvious after 1 month treatment,but after 3 months,there were significant differences among 4 groups （P0.01 or P0.05）,and the combined treatment group was superior than the other three treatment.In the improvement of 3 indexes of liver fibrosis,each treatment group had significant differences after 3 months treatment （P0.01）,and the combined group compared with other groups,the difference had the significance（P0.01）;Hemodynamic examination showed that the diameters of splenic and portal vein as the blood flow were decreased in the groups,the difference had the significance（P0.01）,especially significant in the combined group,besides,the difference of D and Q had the significance in treatment and control group（P0.01）,and there was not statistics significance in each treatment group（P0.05）.Conclusion： The combined treatment of YGSH has the certainly protective efficacy in treatment of hepatitis B patients,its effects are significantly higher than single treatment,and 3 months in the right period of treatment.It can improve liver function,3 indexes of liver fibrosis and hemodynamic changes.